RGEN News and Press, Repligen Corporation From 02/17/22

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% — Record revenue of $670.5 million for the year, and year-over-year growth of 83% — Organic revenue growth of 69% for the fourth quarter and 71% for the year 2021 ...

Repligen (NASDAQ:RGEN) is scheduled to announce Q4 earnings results on Thursday, Feb. 17, before market open. The consensus EPS estimate is $0.65 (+25% Y/Y) and the consensus revenue estimate is $178.27M (+64.1% Y/Y). Over the last 2 years, RGEN has beaten EPS estimates 88% of the time a...

Repligen (NASDAQ:RGEN) launched three advanced affinity chromatography resins for use in gene therapy manufacturing workflows. The company said the resins — AVIPure - AAV9, AVIPure - AAV8, and AVIPure - AAV2 — were developed by its unit Avitide, and are specific t...

WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of three advanced affinity chromatography resins for use in gene therapy manufacturing workflow...

Repligen has seen another few very strong years, as its capital allocation track record remains impressive. The company has furthermore benefited from the pandemic, as organic growth has been very strong as well. I like the long-term potential, and while shares have seen a recent ...

WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 11th Annual SVB Leerink Healthcare Conference being held Feb. 14-18, 2022....

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022. The Company will issue a press release before the market opens and will h...

Bruker Corporation has been performing exceptionally well as of late, driven by strong sales growth and an increase in profits. However, it's uncertain whether recent moves higher on its top and bottom lines are here to stay. At best, shares look to be fairly valued, with the poss...

As a sector, healthcare can be hit or miss for investors. Many companies end up going bust, but some go on to multibagger returns that could help set you up for life. Repligen (NASDAQ: RGEN) and ResMed (NYSE: RMD) are two stocks which could fit that bill with their p...